Genpharmasec Share Price
1.26+0.02 (+1.61%)
-34.72% past 1 Year
Adi Rasayan Ltd is engaged in manufacturing and trading in organic and inorganic chemicals dyes and pigments.
Corporate filings & documents
Announcements
Intimation of Book Closure for AGM to be held on 29th September 2026.
2 days agoIntimation of Book Closure for AGM to be held on 29th September 2026.
2 days agoOutcome of the Meeting of Board of Directors held on Wednesday 02nd September 2026.
2 days agoOutcome of the Meeting of Board of Directors held on Wednesday 02nd September 2026.
2 days agoOutcome of the Meeting of Board of Directors held on Wednesday 02nd September 2026.
2 days agoOutcome of the Meeting of Board of Directors held on Wednesday 02nd September 2026.
2 days agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Sadhwani & PACs
2 days agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Sadhwani & PACs
2 days agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Sadhwani
4 days agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Rajesh Sadhwani
4 days agoGenpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 inter alia to consider and approve 1. To Fix the Day Date Time and Mode of 34th Annual General Meeting of the Company for the year ended March 31 2026 and approve Draft notice and Calendar of Events for the same. 2. To Fix the Cut- off date to determine the entitlement of voting rights of members for E-voting and to fix the commencement and closing date for E-voting. 3. To consider and approve the Directors Report for the year ended March 31 2026. 4. To consider and approve Annual Report for Financial Year 2025-26. 5. To approve closure of Share Transfer Books & Register of Members for the 34th Annual General Meeting. 6. To Consider and approve the appointment of Scrutinizer for E-voting at the ensuing 34th Annual General Meeting. 7. Any other Matter with the permission of the Chairman.
1 week agoGenpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 inter alia to consider and approve 1. To Fix the Day Date Time and Mode of 34th Annual General Meeting of the Company for the year ended March 31 2026 and approve Draft notice and Calendar of Events for the same. 2. To Fix the Cut- off date to determine the entitlement of voting rights of members for E-voting and to fix the commencement and closing date for E-voting. 3. To consider and approve the Directors Report for the year ended March 31 2026. 4. To consider and approve Annual Report for Financial Year 2025-26. 5. To approve closure of Share Transfer Books & Register of Members for the 34th Annual General Meeting. 6. To Consider and approve the appointment of Scrutinizer for E-voting at the ensuing 34th Annual General Meeting. 7. Any other Matter with the permission of the Chairman.
1 week agoRegarding Recent Agreement with Amneal Healthcare Private Limited
3 weeks agoRegarding Recent Agreement with Amneal Healthcare Private Limited
3 weeks agoNewspaper Publication of Unaudited Financial Results for the quarter ended 30th June 2026.
3 weeks agoNewspaper Publication of Unaudited Financial Results for the quarter ended 30th June 2026.
3 weeks agoStatement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th June 2026.
3 weeks agoStatement of deviation or variation in the use of proceeds of Rights Issue for the Quarter ended 30th June 2026.
3 weeks agoUnaudited Standalone & Consolidated Financial Results of the company for the quarter ended 30th June 2026.
3 weeks agoUnaudited Standalone & Consolidated Financial Results of the company for the quarter ended 30th June 2026.
3 weeks agoOutcome of the Meeting of Board of Directors held on Tuesday 11th August 2026.
3 weeks agoOutcome of the Meeting of Board of Directors held on Tuesday 11th August 2026.
3 weeks agoGenpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve 1. To consider and approve Un-audited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report for the quarter ended 30th June 2026. 2. To consider any other business with the permission of a Chairman.
1 month agoGenpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 inter alia to consider and approve 1. To consider and approve Un-audited Standalone and Consolidated Financial Results of the Company along with the Limited Review Report for the quarter ended 30th June 2026. 2. To consider any other business with the permission of a Chairman.
1 month agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended June 30 2026.
1 month agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended June 30 2026.
1 month agoIntimation of Closure of Trading Window
2 months agoIntimation of Closure of Trading Window
2 months agoAnnual Secretarial Compliance Report for the year ended March 31 2026.
3 months agoAnnual Secretarial Compliance Report for the year ended March 31 2026.
3 months agoNewspaper Publication of Audited Financial Result for the quarter and year ended 31st March 2026.
3 months agoNewspaper Publication of Audited Financial Result for the quarter and year ended 31st March 2026.
3 months agoStatement of deviation or variation in the use of proceeds of Rights issue for the Quarter ended 31st March 2026.
3 months agoStatement of deviation or variation in the use of proceeds of Rights issue for the Quarter ended 31st March 2026.
3 months agoAudited Standalone & Consolidated Financial Results of the company for the Quarter and Financial year Ended 31st March 2026.
3 months agoAudited Standalone & Consolidated Financial Results of the company for the Quarter and Financial year Ended 31st March 2026.
3 months agoOutcome of the Meeting of Board of Directors held on Thursday May 21 2026.
3 months agoOutcome of the Meeting of Board of Directors held on Thursday May 21 2026.
3 months agoGenpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve 1. To consider approve & take on record the Audited Standalone and Consolidated Financial Results of the Company along with the Auditors Report thereon for the Quarter and Year ended 31st March 2026.2. To consider any other business with the permission of a Chairman of the Meeting.
3 months agoGenpharmasec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 inter alia to consider and approve 1. To consider approve & take on record the Audited Standalone and Consolidated Financial Results of the Company along with the Auditors Report thereon for the Quarter and Year ended 31st March 2026.2. To consider any other business with the permission of a Chairman of the Meeting.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Genpharmasec Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24231MH1992PLC323914</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Hardik Makwana <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Mr Sohan Chaturvedi <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 14/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Genpharmasec Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24231MH1992PLC323914</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Hardik Makwana <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Mr Sohan Chaturvedi <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 14/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended March 31 2026.
4 months agoCertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended March 31 2026.
4 months agoIntimation of closure of Trading window.
5 months agoIntimation of closure of Trading window.
5 months agoOutcome of Separate Meeting of Independent Directors held on March 24 2026.
5 months agoOutcome of Separate Meeting of Independent Directors held on March 24 2026.
5 months agoNewspaper Publication of Unaudited Financial Result for the quarter ended December 31 2025.
6 months agoStatement of deviation or variation in the use of proceeds of Rights issue for the Quarter ended 31st December 2025.
6 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2024-01-09
Rights
1:1;1.75
Company details
Registered office
Office No.104 & 105 (1st Floor) Gundecha Industrial Premises Co-operative Society Ltd Akurli Road, Kandivali (East) Mumbai Maharashtra PIN: 400101 Tel No: 8655550242 Fax No: NULL Email: [email protected] / [email protected] Internet: www.genpharmasec.com
Registrars
Office No A 106 & 107, Dattani Plaza, East West Compound, Andheri Kurla Road,Safedpul, Sakinaka, Mumbai-400072022-28520461/462 Office No A 106 & 107, Dattani Plaza East West Compound, Andheri Kurla Road Safedpul, Sakinaka PIN: Tel No: 022-28520461/462 Fax No: NULL Email: [email protected]
Management
Sohan Chaturvedi, Whole Time Director & Chief Financial Officer
Rajesh Sadhwani, Non Independent & Non Executive Director
Sneha Sadhwani, Non Independent & Non Executive Director
Siddhesh Shende, Non Executive Independent Director
Mayur Bhatt, Non Executive Independent Director
Sachin Aphandkar, Non Executive Independent Director
Hardik Makwana, Company Secretary & Compliance Officer
Details
BSE 531592
NSE NULL
ISIN INE861N01036